ngµç×ÓÓÎÏ·

05

¿ÆÑÐÏ£Íû

¹«¹²ÎÀÉúѧԺÁèÎÄ»ª½ÌÊÚÍŶÓÔÚCirculation ResearchÔÓÖ¾½ÒÏþÑо¿ÂÛÎÄ

ÔĶÁÁ¿£º£º£º

¹ú¼ÊÐÄѪ¹ÜÁìÓò¸ßˮƽÆÚ¿¯Circulation ResearchÓÚ¿ËÈÕÔÚÏß½ÒÏþngµç×ÓÓÎÏ·¹«¹²ÎÀÉúÑ§ÔºÓªÑøÑ§ÏµÂÛÎÄ¡°Serum Bioavailable and Free 25-Hydroxyvitamin D Levels, but Not Its Total Level, Are Associated With the Risk of Mortality in Patients With Coronary Artery Disease. Circulation Research. 2018;123:996¨C1007 ¡±£¬ £¬£¬¸ÃÎÄͨѶ×÷ÕßΪngµç×ÓÓÎÏ·¹«¹²ÎÀÉúѧԺÁèÎÄ»ª½ÌÊÚ£¬ £¬£¬µÚ1×÷ÕßΪÆä²©Ê¿Ñо¿ÉúÓ೬¡¢¡¢Ñ¦àÚÁÁ¡£¸ÃÎÄÒýÆðÖ÷±àµÄ¹Ø×¢£¬ £¬£¬²¢»ñµÃCirculation ResearchÌâΪ¡°Have We Been Measuring the Wrong Form of Vitamin D? Vitamin D as a Prognostic Biomarker for Coronary Artery Disease Mortality¡±µÄͬ¿¯ÆÀÊö¡£

Ê×Ò³|ngµç×ÓÓÎÏ·Öйú¼¯ÍŹٷ½ÍøÕ¾

Kaplan-Meier plots for all-cause mortality (A) and cardiovascular mortality (B) according to bioavailable 25-hydroxyvitamin D [25(OH)D] quartiles, and all-cause mortality (C) and cardiovascular mortality (D) according to free 25(OH)D quartiles among patients with coronary artery disease.

Ê×Ò³|ngµç×ÓÓÎÏ·Öйú¼¯ÍŹٷ½ÍøÕ¾

Multivariable-adjusted spline functions demonstrate the relation between bioavailable 25-hydroxyvitamin D and all-cause mortality (A) and cardiovascular mortality (B), and the relation between free 25-hydroxyvitamin D and all-cause mortality (C) and cardiovascular mortality (D). The histogram of the distribution of bioavailable or free 25-hydroxyvitamin D levels is also shown. Deaths were shown in dark brown column, and survivals were shown in light brown column.

άÉúËØDÊÇÒ»ÖÖÖ¬ÈÜÐÔάÉúËØ£¬ £¬£¬Ò²ÊÇÒ»Ö̴ֹ¼Àà¼¤ËØÇ°Ì壬 £¬£¬Ó뿵½¡Ç×½üÏà¹Ø¡£ÏÖÔÚ£¬ £¬£¬È«Çò´ó´ó¶¼Ñо¿¾ùÒÔÑ­»·25-OH-DÆÀ¼ÛÈËÌåάÉúËØD״̬£¬ £¬£¬ÒÔ¼°ÆäÓëÂý²¡µÄ¹ØÁª£¬ £¬£¬µ«Ð§¹û²¢·×ÆçÖ¡£åÇÀ´£¬ £¬£¬¶àÏîËæ»ú±ÈÕÕÑо¿£¨RCT£©Ò²·¢Ã÷£¬ £¬£¬²¢·ÇËùÓС°Î¬ÉúËØDȱ·¦¡±»¼Õß¶¼¿ÉÒÔ´ÓάÉúËØDÔö²¹ÖлñÒæ£¬ £¬£¬ÌáÐѹŰå±ê¼ÇÎï²¢²»¿ÉÆÀ¼ÛάÉúËØDµÄÉúÎï¿ÉʹÓÃ״̬¡£ÁèÎÄ»ª½ÌÊÚÍŶÓͨ¹ý¶ÔÆä¿ÎÌâ×éÒѽ¨ÉèµÄ¡°¹ã¶«¹ÚÐIJ¡ÐÐÁС±»¼Õß»ùÏßѪÇåµÄ¶àÏîάÉúËØD±ê¼ÇÎï¼ì²â£¬ £¬£¬¾­ÖÐλ6.7ÄêËæ·Ãºó·¢Ã÷£¬ £¬£¬ÉúÎï¿ÉʹÓÃάÉúËØD£¨BioD£©¼°ÓÎÀëάÉúËØD£¨Free D£©Ë®Æ½£¬ £¬£¬¶ø²»ÊǹŰå±ê¼ÇÎï25-OH-D£¬ £¬£¬¿É×ÔÁ¦Ô¤²â¹ÚÐIJ¡»¼ÕßµÄéæÃü·çÏÕ¡£Ñо¿ÌáÐÑѪÇå BioDºÍFreeDˮƽ¶Ô¹ÚÐIJ¡·çÏÕÆÀ¹À¸üÓмÛÖµ£¬ £¬£¬25-OH-DÊÇ·ñΪºÏÊʵķ´Ó³Î¬ÉúËØD״̬µÄ±ê¼ÇÎïÖµµÃ½øÒ»²½Ñо¿¡£Ñо¿ÎªÑ¡Ôñ׼ȷµÄѪÇåάÉúËØD±ê¼ÇÎïÀ´Ô¤²â¹ÚÐIJ¡»¼ÕßµÄÔ¤ºóÌṩÁËÖ÷ÒªµÄ¿ÆÑ§ÒÀ¾Ý¡£

ÂÛÎÄÁ´½Ó£º£º£ºhttps://www.ahajournals.org/doi/pdf/10.1161/CIRCRESAHA.118.313558

ͬ¿¯ÆÀÊöÁ´½Ó£º£º£ºhttps://www.ahajournals.org/doi/pdf/10.1161/CIRCRESAHA.118.313814

¡¾ÍøÕ¾µØÍ¼¡¿